SEC Form 4 · accession 0000899243-19-006657
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lawrence Otto Klein
Officer — Chief Business Officer
Period of report
Mar 5, 2019
Accepted (ET)
Mar 7, 2019 · 4:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $40.87 | Mar 5, 2019 | A | 45,000 | A | — | Mar 5, 2029 | Common Shares | 45,000 | 45,000 | D |
Explanation of responses
- F1This option was granted on March 5, 2019 with respect to 45,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019.